Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease
Pooled result · Composite kidney outcomeResult — go to the resultRelative risk 0.71 95% CI 0.53–0.94Authors' conclusion
SGLT2i showed the broadest cardiorenal benefits, while finerenone and semaglutide provided additional protection across selected outcomes. Finerenone increased hyperkalaemia and treatment discontinuation.
Study context
- Population
- Adults with T2D and diabetic kidney disease (DKD) in randomised trials (PubMed, Embase, CENTRAL searched through July 9, 2026)10 randomised datasets
- Participants
- 37,923 adults
- Comparison
- Finerenone, SGLT2i, semaglutide and finerenone-SGLT2i combination vs control and each other
- Outcome
- Cardiovascular composite:
- Events
- Composite kidney outcomes
Methodological detailsfrequentist network meta-analysis
- Frequentist network meta-analysis
Pooled result
Composite kidney outcome
Relative risk
0.71
95% CI 0.53–0.94
Dapagliflozinvs Semaglutide
RR 0.71 (95% CI 0.53–0.94)
As reported in the abstract
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| HyperkalaemiaFinerenonevs Control | 2.03 (1.82–2.26) | |
| HyperkalaemiaFinerenone plus empagliflozinvs Empagliflozin | 2.48 (1.22–5.06) | |
| Treatment discontinuation due to adverse eventsFinerenonevs Control | 1.18 (1.02–1.35) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. Diabetes Obes Metab. Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →